<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01703949</url>
  </required_header>
  <id_info>
    <org_study_id>7808</org_study_id>
    <secondary_id>NCI-2012-01696</secondary_id>
    <secondary_id>7808</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG1713010</secondary_id>
    <nct_id>NCT01703949</nct_id>
  </id_info>
  <brief_title>Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma</brief_title>
  <official_title>A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients With CD30+ Malignancies Refractory to Every â‰¥ 3 Week Brentuximab Vedotin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II pilot trial studies how well brentuximab vedotin with or without nivolumab&#xD;
      works in treating patients with CD30+ lymphoma that has come back after a period of&#xD;
      improvement or does not respond to treatment. Biological therapies, such as brentuximab&#xD;
      vedotin, may stimulate the immune system in different ways and stop cancer cells from&#xD;
      growing. Monoclonal antibodies, such as nivolumab may interfere with the ability of tumor&#xD;
      cells to grow and spread. Giving brentuximab vedotin with or without nivolumab may work&#xD;
      better in treating patients with CD30+ lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      ARM A (CLOSED TO ACCRUAL): Patients receive brentuximab vedotin intravenously (IV) over 30&#xD;
      minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM B: Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30-60&#xD;
      minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 3-5 weeks, every 3 months&#xD;
      for 1 year, and then every 6 months for 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2013</start_date>
  <completion_date type="Anticipated">January 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate as measured by the Cheson 2007 criteria</measure>
    <time_frame>Up to 5 weeks after completion of study treatment</time_frame>
    <description>No formal statistical measures will be pre-specified. This protocol will be deemed a &quot;success&quot; if the absolute response rate in this group of patients is &gt;= 20%.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Recurrent Hodgkin Lymphoma</condition>
  <condition>Recurrent Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Hodgkin Lymphoma</condition>
  <condition>Refractory Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A (brentuximab vedotin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (brentuximab vedotin, nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (brentuximab vedotin)</arm_group_label>
    <arm_group_label>Arm B (brentuximab vedotin, nivolumab)</arm_group_label>
    <other_name>ADC SGN-35</other_name>
    <other_name>Adcetris</other_name>
    <other_name>Anti-CD30 Antibody-Drug Conjugate SGN-35</other_name>
    <other_name>Anti-CD30 Monoclonal Antibody-MMAE SGN-35</other_name>
    <other_name>Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35</other_name>
    <other_name>cAC10-vcMMAE</other_name>
    <other_name>SGN-35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (brentuximab vedotin)</arm_group_label>
    <arm_group_label>Arm B (brentuximab vedotin, nivolumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (brentuximab vedotin, nivolumab)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>NIVO</other_name>
    <other_name>ONO-4538</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed or refractory CD30+ lymphoma that has either achieved &lt; PR to brentuximab&#xD;
             vedotin (minimum of 2 cycles), progressed while receiving brentuximab vedotin, or&#xD;
             progressed within 6 months of the last dose of brentuximab vedotin&#xD;
&#xD;
          -  Documented expression of CD30 on tumor cells&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1,000/uL&#xD;
&#xD;
          -  Platelets &gt; 50,000/uL&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 mg/dL OR creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 x ULN&#xD;
&#xD;
          -  Measurable disease by computed tomography (CT) or similar (e.g. magnetic resonance&#xD;
             imaging [MRI]) criteria (&gt; 1.5 cm)&#xD;
&#xD;
          -  Resolution of all non-hematologic brentuximab vedotin-related adverse events (AEs) to&#xD;
             &lt; grade 2&#xD;
&#xD;
          -  All patients must be informed of the investigational nature of this study and have&#xD;
             given written consent in accordance with institutional and federal guidelines&#xD;
&#xD;
          -  Patients must be anticipated to complete at least 2 cycles of chemotherapy on study&#xD;
&#xD;
          -  Expected survival if untreated of &gt; 90 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior transplant within 100 days&#xD;
&#xD;
          -  Radioimmunotherapy within 12 weeks&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) or hepatitis B positivity or prior&#xD;
             progressive multifocal leukoencephalopathy (PML)&#xD;
&#xD;
          -  Active infection or other medical condition which would preclude treatment in the&#xD;
             opinion of the principal investigator; this would include a corrected diffusing&#xD;
             capacity of the lungs for carbon monoxide (DLCO) of &lt; 60% predicted or symptomatic&#xD;
             interstitial lung disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt; 2&#xD;
&#xD;
          -  Known active central nervous system (CNS) involvement&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 1 if due to brentuximab vedotin or any peripheral&#xD;
             neuropathy &gt; grade 2&#xD;
&#xD;
          -  Intolerance to brentuximab vedotin&#xD;
&#xD;
          -  Concurrent use of other anti-cancer agents or experimental treatments&#xD;
&#xD;
          -  No current or prior autoimmune disease with the exception of vitiligo and autoimmune&#xD;
             alopecia (Arm B only)&#xD;
&#xD;
          -  Pregnancy or breastfeeding; (females of childbearing potential must have a negative&#xD;
             serum or urine beta human chorionic gonadotropin [beta-hCG] pregnancy test result&#xD;
             within 7 days prior to the first dose of brentuximab vedotin; females with false&#xD;
             positive results and documented verification that the patient is not pregnant are&#xD;
             eligible for participation; females of non-childbearing potential are those who are&#xD;
             postmenopausal greater than 1 year or who have had a bilateral tubal ligation or&#xD;
             hysterectomy; females of childbearing potential and males who have partners of&#xD;
             childbearing potential must agree to use 2 effective contraceptive methods during the&#xD;
             study and for 6 months following the last dose of brentuximab vedotin or 8 months&#xD;
             following the last dose of nivolumab, whichever is later)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay K. Gopal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ajay K. Gopal</last_name>
    <phone>206-606-2037</phone>
    <email>agopal@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajay K. Gopal</last_name>
      <phone>206-606-2037</phone>
      <email>agopal@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Ajay K. Gopal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 8, 2012</study_first_submitted>
  <study_first_submitted_qc>October 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2012</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Brentuximab Vedotin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

